Loading...

INDP INDAPTUS THERAPEUTICS INC Contract Awards 8-K Filing

NDPT

NDP

INDAPTUS THERAPEUTICS INC

(INDP)

2024 8-K

Show Summary

Summary

Equity Offerings

Reverse Stock Split

Private Placement

Financial Statements

Financial Results

Equity Purchase Agreement

Nasdaq Compliance

Private Placement

Securities Offering

Financial Results

Clinical Supply Agreement

Financial Results

Securities Purchase Agreements

Annual Meeting and Plan Ame...

Phase I Trial Advancement

Financial Results Announcement

Research Presentation

Financial Results Announcement

Positive Trial Results

Bylaws Amendments

Financial Results Announcement

Interim Data Presentation

Interim Data Release

Financial Results Announcement

Clinical Trial Update

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Appointment of Director

External Links:

Indaptus Therapeutics has signed a clinical supply agreement with BeiGene to advance a study combining their cancer treatment, Decoy20, with BeiGene's tislelizumab, aiming for FDA approval to start the study in 2025.

AI Assistant

INDAPTUS THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.